Lv74
5005 积分 2021-04-27 加入
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
14天前
已完结
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
14天前
已完结
Defining genome-wide CRISPR–Cas genome-editing nuclease activity with GUIDE-seq
26天前
已完结
FAS-less allogeneic CAR T cells
1个月前
已完结
Ablation of FAS confers allogeneic CD3– CAR T cells with resistance to rejection by T cells and natural killer cells
1个月前
已完结
Engineering immune-evasive allogeneic cellular immunotherapies
2个月前
已完结
HIV immune evasin Nef enhances allogeneic CAR T cell potency
2个月前
已完结
Virus-free CRISPR knock-in of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells
2个月前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
3个月前
已完结
CAR-T cell therapy: Challenge and opportunity for effective treatment of small cell lung cancer
3个月前
已完结
皖公网安备34019202002308
